Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
Autor: | Mark A. Socinski, Shaker R. Dakhil, Corey J. Langer, Markus F. Renschler, Ray D. Page, Hui Zhang, J. Orsini, Vera Hirsh, Jeremy K. Hon, Isamu Okamoto |
---|---|
Rok vydání: | 2012 |
Předmět: |
Oncology
Adult Male medicine.medical_specialty Aging Lung Neoplasms Neutropenia Paclitaxel Disease-Free Survival law.invention Carboplatin chemistry.chemical_compound Randomized controlled trial law Internal medicine Albumins Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Progression-free survival Lung cancer Survival rate Aged Aged 80 and over business.industry Hematology Middle Aged medicine.disease Clinical trial Survival Rate Treatment Outcome chemistry Female business |
Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 24(2) |
ISSN: | 1569-8041 |
Popis: | This analysis evaluates safety and efficacy in elderly (≥ 70 years old) versus younger patients enrolled in a phase III advanced non-small-cell lung cancer (NSCLC) trial.Untreated stage IIIB/IV patients with PS 0/1 were randomly assigned (1:1) to carboplatin AUC6, day 1 every 3 weeks, and either nab-paclitaxel (Abraxane) 100 mg/m(2) weekly (nab-P/C) or solvent-based paclitaxel (Taxol) 200 mg/m(2) day 1 every 3 weeks (sb-P/C). The primary end-point was overall response rate (ORR).Fifteen percent of 1052 enrolled patients were elderly: nab-P/C, n = 74; sb-P/C, n = 82. In both age cohorts, the ORR was higher with nab-P/C versus sb-P/C (age ≥ 70: 34% versus 24%, P = 0.196; age70: 32% versus 25%, P = 0.013). In elderly patients, progression-free survival (PFS) trended in favor of nab-P/C (median 8.0 versus 6.8 months, hazard ratio (HR) 0.687, P = 0.134), and overall survival (OS) was significantly improved (median 19.9 versus 10.4 months, HR 0.583, P = 0.009). In younger patients, PFS (median 6.0 versus 5.8 months, HR 0.903, P = 0.256) and OS (median 11.4 versus 11.3 months, HR 0.999, P = 0.988) were similar in both arms. Adverse events were similar in both age groups, with less neutropenia (P = 0.015), neuropathy (P = 0.001), and arthralgia (P = 0.029), and increased anemia (P = 0.007) with nab-P/C versus sb-P/C.In elderly NSCLC patients, nab-P/C as first-line therapy was well tolerated and improved the ORR and PFS, with substantially longer OS versus sb-PC. |
Databáze: | OpenAIRE |
Externí odkaz: |